Form 8-K - Current report:
SEC Accession No. 0000950170-21-000344
Filing Date
2021-06-11
Accepted
2021-06-11 07:00:33
Documents
15
Period of Report
2021-06-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eq-20210611.htm   iXBRL 8-K 46605
2 EX-99.1 eq-20210611ex99_1.htm EX-99.1 55691
3 GRAPHIC img65627548_0.jpg GRAPHIC 200272
4 GRAPHIC img65627548_1.jpg GRAPHIC 200272
  Complete submission text file 0000950170-21-000344.txt   783400

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eq-20210611_lab.xml EX-101.LAB 14046
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eq-20210611_pre.xml EX-101.PRE 10378
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eq-20210611.xsd EX-101.SCH 2435
8 EXTRACTED XBRL INSTANCE DOCUMENT eq-20210611_htm.xml XML 4886
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38692 | Film No.: 211009944
SIC: 2834 Pharmaceutical Preparations